Pyrazinamide
TREATMENT
Pyrazinamide (15-30 mg/kg PO q24h [maximum, 2 g] or 50-75 mg/kg PO twice a week [maximum, 4 g/dose]) kills mycobacteria by an unknown disruption of membrane transport. It is well absorbed orally and widely distributed throughout the body, including the CSF. Pyrazinamide is typically used for the first 2 months of therapy during treatment of active TB.
SPECIAL CONSIDERATIONS
Adverse events include hyperuricemia and hepatitis.
More medical literature on Medic.Studio
More on the topic Pyrazinamide:
- Pyrazinamide
- Sideroblastic Anemias
- Tuberculosis Caused by M. bovis in Humans in Uganda
- Nontuberculous Mycobacteria
- Bacterial infections
- Monoclonal Gammopathy of Unknown Significance
- Drug Susceptibility Testing Definition and Description
- Disruption
- Macrovascular Complications of Diabetes Mellitus
-
Infectious diseases -
Internal diseases -
Obstetrics and Gynaecology -
Pediatrics -
Veterinary medicine -
-
Conflictology -
Ecology -
Economy -
Finance -
History -
Law -
Medicine -
Philosophy -
Religious studies -